STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability
Luo, T., K. Masson, J. D. Jaffe, W. Silkworth, N. T. Ross, C. A. Scherer, C. Scholl, et al. 2012. “STK33 Kinase Inhibitor BRD-8899 Has No Effect on KRAS-Dependent Cancer Cell Viability”. Proc Natl Acad Sci U S A 109: 2860-5.